Roswell Park Cancer Institute-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Roswell Park Cancer Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013586
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Roswell Park Cancer Institute (RPCI) is a cancer treatment institute that provides diagnosis, treatments and services for various kinds of cancer. The institute’s treatment includes advanced endoscopy, BMT, interventional pulmonology, interventional radiology, anesthesiologists, psychologists, nurses, phisical andoccupational therapists, nutritionists, photodynamic therapy, radiation medicine, robotics and surgery. Its research departments comprise biostatistics and bioinformatics, endocrinology, cancer genetics, palliative care, endocrinology, endoscopy center, pain management, drug profile, cancer prevention and control, cell stress biology, health behavior, immunology, molecular and cellular biology, pharmacology and therapeutic, among others. The institute also provides educational services through various PhD, master, residency, clinical fellowships, post doctoral program and summer programs in the areas of biophysics, biochemistry, immunology, genomics and cancer pathology. RPCI is headquartered in Buffalo, New York, the US.

Roswell Park Cancer Institute – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Roswell Park Cancer Institute, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Roswell Park Cancer Institute, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Roswell Park Cancer Institute, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Roswell Park Cancer Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Roswell Park Cancer Institute, Medical Devices Deals, 2011 to YTD 2017 9
Roswell Park Cancer Institute, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Roswell Park Cancer Institute, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
MimiVax Raises Funds through Seed Financing 11
Partnerships 12
Roswell Park Cancer Institute Enters into Co-Development Agreement with Center Of Molecular Immunology 12
Roswell Park Cancer Institute And Jasco Pharma Enter Into Agreement To Advance JP_11646 13
Licensing Agreements 14
MimiVax Enters into Licensing Agreement with Roswell Park Cancer Institute 14
Ceno Technologies Enters Into Licensing Agreement With Roswell Park Cancer Institute 15
OncoTartis Enters into Licensing Agreement with Roswell Park Cancer Institute 16
Panacela Labs Enters into Licensing Agreement with Roswell Park Cancer Institute 17
Roswell Park Cancer Institute – Key Competitors 18
Roswell Park Cancer Institute – Key Employees 19
Roswell Park Cancer Institute – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Government and Public Interest 22
Sep 19, 2017: Roswell Park Draws More Than $6.8 Million for Research on New Treatments and Supportive-Care Approaches 22
Sep 07, 2017: Multivitamins May Reduce Incidence of Neuropathy from Chemotherapy 23
May 05, 2017: Research Supports Use of Enhanced Recovery Approaches in More Abdominal Surgeries 24
Apr 03, 2017: Roswell Park Team Identifies Potential Biomarker for Aggressive Prostate Cancer 25
Mar 03, 2017: Roswell Park Researchers Garner Nearly $2.8 Million for Studies on Origins, Effects and Treatment of Cancer 26
Jan 10, 2017: Unique Gene Signature Predicts Potentially Lethal Prostate Cancers 28
Jan 09, 2017: Roswell Park Researchers Offer Novel Insight into Genetic Changes Leading to Cancer 29
Dec 28, 2016: New Study Highlights Role for Immune Cells in Cancer’s Ability to Evade Immunotherapy 30
Nov 17, 2016: Roswell Park Analysis: Risk Stratification Tool Accurately Predicts Prostate Cancer Progression 31
Oct 17, 2016: Monitoring Vitamin D Levels May Benefit Childhood Cancer Survivors 32
Jul 27, 2016: Infusion of Nearly $35.4 Million in Grant Funding to Support Roswell Park Research 33
Jul 22, 2016: Vitamin D Receptor Protein May Reduce Odds of Being Diagnosed with Aggressive Breast Cancer 35
Apr 20, 2016: Study Supports Evidence that Rab Disruption May Be Effective Strategy for Treating Multiple Myeloma 36
Apr 19, 2016: Multivitamin Use Protects Against Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients 37
Apr 19, 2016: Combination Therapy Incorporating 3 New Agents Shows Promise As Treatment for Aggressive Lymphoma 38
Jan 26, 2016: Study Identifies New Class of Anticancer Compounds for Possible Targeted Therapy in Blood Cancers 39
Product News 40
May 06, 2016: Researchers Report Progress as They Develop New Approach to Treating Metastatic Melanoma 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Roswell Park Cancer Institute, Pharmaceuticals & Healthcare, Key Facts 2
Roswell Park Cancer Institute, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Roswell Park Cancer Institute, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Roswell Park Cancer Institute, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Roswell Park Cancer Institute, Deals By Therapy Area, 2011 to YTD 2017 8
Roswell Park Cancer Institute, Medical Devices Deals, 2011 to YTD 2017 9
Roswell Park Cancer Institute, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
MimiVax Raises Funds through Seed Financing 11
Roswell Park Cancer Institute Enters into Co-Development Agreement with Center Of Molecular Immunology 12
Roswell Park Cancer Institute And Jasco Pharma Enter Into Agreement To Advance JP_11646 13
MimiVax Enters into Licensing Agreement with Roswell Park Cancer Institute 14
Ceno Technologies Enters Into Licensing Agreement With Roswell Park Cancer Institute 15
OncoTartis Enters into Licensing Agreement with Roswell Park Cancer Institute 16
Panacela Labs Enters into Licensing Agreement with Roswell Park Cancer Institute 17
Roswell Park Cancer Institute, Key Competitors 18
Roswell Park Cancer Institute, Key Employees 19
Roswell Park Cancer Institute, Subsidiaries 21

★海外企業調査レポート[Roswell Park Cancer Institute-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Konami Holdings Corp:企業の戦略・SWOT・財務情報
    Konami Holdings Corp - Strategy, SWOT and Corporate Finance Report Summary Konami Holdings Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Gamma Medica Inc-医療機器分野:企業M&A・提携分析
    Summary Gamma Medica Inc (Gamma Medica), formerly Gamma Medica Ideas Inc is a medical device company that offers imaging solutions. The company designs, develops and manufactures imaging systems for clinical and pre-clinical applications. It offers lumagem, lumagem mbi workflow, lumagem procedure ov …
  • Suven Life Sciences Ltd (SUVEN):企業の財務・戦略的SWOT分析
    Summary Suven Life Sciences Ltd (Suven) formerly Suven Pharmaceuticals Pvt Ltd designs, develops, manufactures and supplies bulk actives, drug intermediates and fine chemicals. The company offers active pharmaceutical ingredient products which include aripiprazole, calcium acetate, divalproex sodium …
  • Samsung Heavy Industries Co., Ltd.
    Samsung Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Samsung Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Turner & Townsend Plc:企業の戦略的SWOT分析
    Turner & Townsend Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Elders Limited:企業の戦略・SWOT・財務情報
    Elders Limited - Strategy, SWOT and Corporate Finance Report Summary Elders Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Telekom Austria AG:企業の戦略・SWOT・財務情報
    Telekom Austria AG - Strategy, SWOT and Corporate Finance Report Summary Telekom Austria AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Xspray Pharma AB (XSPRAY):製薬・医療:M&Aディール及び事業提携情報
    Summary Xspray Pharma AB (Xspray Pharma), formerly Xspray Microparticles AB, is a drug development company that develops and commercializes protein kinase inhibitors (PKI) for targeted cancer treatments. The company’s drug candidates include HyNap-Dasa, HyNap-Nilo and HyNap-Sora. Its protein kinase …
  • Endonovo Therapeutics Inc (ENDV):企業の製品パイプライン分析2018
    Summary Endonovo Therapeutics Inc (Endonovo Therapeutics) is a commercial stage development company that offers non-invasive medical devices and equipment. The company’s products include Electroceutical Therapy a FDA-Cleared for the palliative treatment of pain and post-surgical edema and CE Marked …
  • Bare Escentuals Inc.:企業の戦略的SWOT分析
    Bare Escentuals Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Heidelberg Pharma AG (WL6):製薬・医療:M&Aディール及び事業提携情報
    Summary Heidelberg Pharma AG (Heidelberg Pharma) formerly, Wilex AG is a biopharmaceutical company. The company develops therapeutic and diagnostic product candidates for the treatment and specific detection of various cancers. Heidelberg Pharma’s pipeline products are focused on treating multiple m …
  • Qatar Petroleum-石油・ガス分野:企業M&A・提携分析
    Summary Qatar Petroleum (QP) is a state-owned oil and gas company. The company, along with subsidiaries, affiliates and joint ventures, undertake the exploration, drilling, production, storage, transportation, marketing and sale of crude oil, natural gas and gas liquids, liquefied natural gas (LNG), …
  • ImevaX GmbH-製薬・医療分野:企業M&A・提携分析
    Summary ImevaX GmbH (ImevaX) is a biopharmaceutical company that develops specific vaccines against chronic infections. The company identifies and uses immune modulatory bacterial factors to develop specific vaccines. It develops specific vaccines against pathogens that cause chronic infectious dise …
  • Aviakompaniya Sibir” OAO (P):企業の戦略・SWOT・財務分析
    Aviakompaniya Sibir'' OAO (P) - Strategy, SWOT and Corporate Finance Report Summary Aviakompaniya Sibir'' OAO (P) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • TOP Ships Inc. (TOPS):企業の財務・戦略的SWOT分析
    TOP Ships Inc. (TOPS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • E. & J. Gallo Winery:企業の戦略・SWOT・財務情報
    E. & J. Gallo Winery - Strategy, SWOT and Corporate Finance Report Summary E. & J. Gallo Winery - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Mereo Biopharma Group Plc (MPH):製薬・医療:M&Aディール及び事業提携情報
    Summary Mereo Biopharma Group Plc (Mereo), formerly Mereo Biopharma Group Ltd is a specialty bio-pharmaceutical company which develops novel medicines for the treatment of rare and specialty diseases. The company’s pipeline products include BPS-804, which is used for the treatment of brittle bone sy …
  • Planmeca Oy:企業の戦略的SWOT分析
    Planmeca Oy - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Biocept Inc (BIOC):企業の財務・戦略的SWOT分析
    Summary Biocept Inc (Biocept) is a molecular diagnostics company. The company develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. It offers assays for solid tumor indications, such as breast cancer, non-small cell l …
  • Univar Solutions Inc (UNVR):企業の財務・戦略的SWOT分析
    Univar Solutions Inc (UNVR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆